Neurotech International

Neurotech International EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Neurotech International (NTI.AX) as of Nov 4, 2026 is -412.47 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -342.20 % — a change of 20.54% (lower).

EBIT/Assets

-412.47 %

YoY

20.54%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Neurotech International is 2026 -412.47 % . Operating Income to Assets Ratio (EBIT/Assets) of Neurotech International was 2025 -342.20 % . It decreases by 20.54% lower compared to the previous year.

The Neurotech International EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-407.92 AUD
Jan 1, 2020
-1,601.32 AUD
Jan 1, 2021
-148.73 AUD
Jan 1, 2022
-194.30 AUD
Jan 1, 2023
-169.88 AUD
Jan 1, 2024
-71.73 AUD
Jan 1, 2025
-342.20 AUD
Jan 1, 2026
-412.47 AUD
The Neurotech International EBIT/Assets history
YEAREBIT/AssetsYoY
-412.47 %+20.54%
-342.20 %+377.06%
-71.73 %-57.77%
-169.88 %-12.57%
-194.30 %+30.64%
-148.73 %-90.71%
-1,601.32 %+292.56%
-407.92 %+401.22%
-81.39 %+0.99%
-80.59 %+593.39%
-11.62 %-57.93%
-27.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neurotech International Stock analysis

What does Neurotech International do? Neurotech International Ltd. generates revenue through the development and commercialization of medical devices and solutions, primarily targeting pediatric neurological disorders. The company's key product, Mente Autism, is a portable EEG headband that uses closed-loop neurofeedback to assist children with autism spectrum disorder (ASD) by improving relaxation and engagement. Clinical studies assess the neuro-protective and anti-inflammatory effects of its NTI/Dolce cannabis strains, which are part of its development program NTI164 that completed a Phase I/II trial for ASD treatment. The firm focuses on commercializing these neurological solutions for pediatric use in home therapy settings. The company's primary customers are families and healthcare providers managing children with autism spectrum disorder (ASD). Mente Autism is marketed as a home therapy device to increase engagement and reduce anxiety in autistic children with elevated delta-band brain activity. Neurotech International Ltd. leverages its clinical trial results to support the commercialization of Mente Autism and its NTI/Dolce cannabis strains, which are positioned as therapeutic solutions for neurological conditions. The firm's revenue streams are derived from the sale of Mente Autism devices and the potential future commercialization of its NTI/Dolce cannabis-based products. Neurotech International Ltd. operates within the medical device sector, emphasizing pediatric neurological solutions. Its products, including Mente Autism and the NTI/Dolce cannabis strains, are developed through clinical studies to address specific neurological disorders. The company's focus on home-based therapy for ASD patients differentiates its offerings in the market, targeting a niche segment of families seeking non-invasive, accessible treatments for children with autism. Neurotech International is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurotech International stock

Operating Income to Assets Ratio (EBIT/Assets) of Neurotech International is -412.47 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Neurotech International changed from -342.20 % to -412.47 %, representing a 20.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Neurotech International since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Neurotech International with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Neurotech International

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Neurotech International